JP2001516717A - 選択的5−HT1Aアンタゴニストおよび選択的h5−HT1Bアンタゴニストまたは部分的アゴニストの組み合わせ - Google Patents

選択的5−HT1Aアンタゴニストおよび選択的h5−HT1Bアンタゴニストまたは部分的アゴニストの組み合わせ

Info

Publication number
JP2001516717A
JP2001516717A JP2000511498A JP2000511498A JP2001516717A JP 2001516717 A JP2001516717 A JP 2001516717A JP 2000511498 A JP2000511498 A JP 2000511498A JP 2000511498 A JP2000511498 A JP 2000511498A JP 2001516717 A JP2001516717 A JP 2001516717A
Authority
JP
Japan
Prior art keywords
methylpiperazin
compound
dihydro
benzopyran
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000511498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001516717A5 (cg-RX-API-DMAC10.html
Inventor
ステファン・ベルイ
スヴァーンテ・ロス
セト−オローフ・トゥールベルイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2001516717A publication Critical patent/JP2001516717A/ja
Publication of JP2001516717A5 publication Critical patent/JP2001516717A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000511498A 1997-09-18 1998-09-09 選択的5−HT1Aアンタゴニストおよび選択的h5−HT1Bアンタゴニストまたは部分的アゴニストの組み合わせ Pending JP2001516717A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9703374A SE9703374D0 (sv) 1997-09-18 1997-09-18 A new combination
SE9703374-0 1997-09-18
PCT/SE1998/001600 WO1999013876A1 (en) 1997-09-18 1998-09-09 A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST

Publications (2)

Publication Number Publication Date
JP2001516717A true JP2001516717A (ja) 2001-10-02
JP2001516717A5 JP2001516717A5 (cg-RX-API-DMAC10.html) 2006-01-05

Family

ID=20408294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000511498A Pending JP2001516717A (ja) 1997-09-18 1998-09-09 選択的5−HT1Aアンタゴニストおよび選択的h5−HT1Bアンタゴニストまたは部分的アゴニストの組み合わせ

Country Status (29)

Country Link
US (1) US6159972A (cg-RX-API-DMAC10.html)
EP (1) EP1021183B1 (cg-RX-API-DMAC10.html)
JP (1) JP2001516717A (cg-RX-API-DMAC10.html)
KR (1) KR20010024075A (cg-RX-API-DMAC10.html)
CN (1) CN1182847C (cg-RX-API-DMAC10.html)
AR (1) AR015447A1 (cg-RX-API-DMAC10.html)
AT (1) ATE261728T1 (cg-RX-API-DMAC10.html)
AU (1) AU752718B2 (cg-RX-API-DMAC10.html)
BR (1) BR9812234A (cg-RX-API-DMAC10.html)
CA (1) CA2302383A1 (cg-RX-API-DMAC10.html)
DE (1) DE69822490T2 (cg-RX-API-DMAC10.html)
DK (1) DK1021183T3 (cg-RX-API-DMAC10.html)
EE (1) EE04142B1 (cg-RX-API-DMAC10.html)
ES (1) ES2216307T3 (cg-RX-API-DMAC10.html)
HU (1) HUP0100401A3 (cg-RX-API-DMAC10.html)
IL (1) IL134774A0 (cg-RX-API-DMAC10.html)
IS (1) IS5408A (cg-RX-API-DMAC10.html)
MY (1) MY116281A (cg-RX-API-DMAC10.html)
NO (1) NO20001398L (cg-RX-API-DMAC10.html)
NZ (1) NZ503174A (cg-RX-API-DMAC10.html)
PL (1) PL339370A1 (cg-RX-API-DMAC10.html)
PT (1) PT1021183E (cg-RX-API-DMAC10.html)
RU (1) RU2215528C2 (cg-RX-API-DMAC10.html)
SE (1) SE9703374D0 (cg-RX-API-DMAC10.html)
SK (1) SK2842000A3 (cg-RX-API-DMAC10.html)
TR (1) TR200000734T2 (cg-RX-API-DMAC10.html)
TW (1) TW568786B (cg-RX-API-DMAC10.html)
WO (1) WO1999013876A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA987810B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
USD969018S1 (en) 2021-06-28 2022-11-08 Koninklijke Asscher Diamant Maatschappij B.V. Rose pear diamond article

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA90673B (en) * 1989-02-02 1990-10-31 Yamanouchi Pharma Co Ltd Tetrahydrobenzimidazole derivatives
ES2162792T3 (es) * 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
FI961247A0 (fi) * 1996-03-18 1996-03-18 Finnish Peroxides Ab Oy Foerfarande foer loesning av uppsvaellningsproblem i en avfalls vattenreningsanordning foer kontroll av traodartiga bakterier
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
SK2842000A3 (en) 2000-09-12
AR015447A1 (es) 2001-05-02
AU752718B2 (en) 2002-09-26
EP1021183B1 (en) 2004-03-17
IL134774A0 (en) 2001-04-30
TR200000734T2 (tr) 2000-11-21
MY116281A (en) 2003-12-31
NO20001398D0 (no) 2000-03-17
ZA987810B (en) 1999-02-18
PT1021183E (pt) 2004-07-30
CA2302383A1 (en) 1999-03-25
DK1021183T3 (da) 2004-07-05
CN1182847C (zh) 2005-01-05
RU2215528C2 (ru) 2003-11-10
WO1999013876A1 (en) 1999-03-25
DE69822490T2 (de) 2005-03-03
CN1279609A (zh) 2001-01-10
TW568786B (en) 2004-01-01
US6159972A (en) 2000-12-12
SE9703374D0 (sv) 1997-09-18
HUP0100401A2 (hu) 2002-01-28
ES2216307T3 (es) 2004-10-16
NO20001398L (no) 2000-04-04
HK1032740A1 (en) 2001-08-03
PL339370A1 (en) 2000-12-18
AU9192998A (en) 1999-04-05
NZ503174A (en) 2002-03-01
BR9812234A (pt) 2000-07-18
DE69822490D1 (de) 2004-04-22
IS5408A (is) 2000-03-15
EE04142B1 (et) 2003-10-15
HUP0100401A3 (en) 2003-01-28
ATE261728T1 (de) 2004-04-15
EE200000143A (et) 2001-02-15
KR20010024075A (ko) 2001-03-26
EP1021183A1 (en) 2000-07-26

Similar Documents

Publication Publication Date Title
JP2001516718A (ja) 5−HT再取り込み阻害剤およびh5−HT1Bアンタゴニストまたは部分的アゴニストの組み合わせ
JP2001516719A (ja) モノアミンオキシダーゼ阻害剤およびh5−HT1Bアンタゴニストまたは部分的アゴニストの組み合わせ
JP2001510837A (ja) 置換された1,2,3,4−テトラヒドロナフタレン誘導体
JP4150161B2 (ja) 置換されたクロマン誘導体
JP2001516755A (ja) 置換されたクロマン誘導体
US6159972A (en) Combination of a selective 5-HT1A antagonist and a selective ub. h5-HT.s1B antagonist or partial agonist
JP2002535320A (ja) 新規なモルホリノベンズアミド塩
CZ2000945A3 (cs) Kombinace selektivního antagonisty 5-HT1A a selektivního antagonisty nebo parciárního agonisty h5-HTlB
HK1032740B (en) A combination of a selective 5-ht1a antagonist and a selective h5-ht1b antagonist or partial agonist
CZ2000946A3 (cs) Kombinace inhibitoru vychytávání 5-HT a antagonisty nebo parciárního agonisty h5-HTlB
CZ2000944A3 (cs) Kombinace inhibitoru monoaminoxidázy a antagonisty nebo parciárního agonisty Ii5-HT1B
MXPA00002623A (en) A combination of a selective 5-ht1a
HK1032739B (en) A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist
MXPA00002612A (en) A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090512

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091020